^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor) + PIN-A1 (CK1α degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2799 Anti-Leukemic Effects of CK1α Degrader As Monotherapy and in Combination with Targeted Drugs
Published date:
11/02/2023
Excerpt:
Patient-derived xenograft models from two FLT3-ITD-mutated AML patients also showed potent anti-leukemic effects of PinA1 as monotherapy and in combination with gilteritinib.